Flavopiridol (L86-8275)

Catalog No.S1230 Synonyms: NSC 649890 HCl, HMR-1275, Alvocidib

For research use only.

Flavopiridol (L86-8275, Alvocidib, NSC 649890, HMR-1275) competes with ATP to inhibit CDKs including CDK1, CDK2, CDK4, CDK6, and CDK9 with IC50 values in the 20-100 nM range. It is more selective for CDK1, 2, 4, 6, 9 versus CDK7. Flavopiridol is initially found to inhibit EGFR and PKA. Flavopiridol induces autophagy and ER stress. Flavopiridol blocks HIV-1 replication. Phase 1/2.

Flavopiridol (L86-8275) Chemical Structure

CAS No. 146426-40-6

Selleck's Flavopiridol (L86-8275) has been cited by 99 publications

Purity & Quality Control

Choose Selective CDK Inhibitors

Other CDK Products

Biological Activity

Description Flavopiridol (L86-8275, Alvocidib, NSC 649890, HMR-1275) competes with ATP to inhibit CDKs including CDK1, CDK2, CDK4, CDK6, and CDK9 with IC50 values in the 20-100 nM range. It is more selective for CDK1, 2, 4, 6, 9 versus CDK7. Flavopiridol is initially found to inhibit EGFR and PKA. Flavopiridol induces autophagy and ER stress. Flavopiridol blocks HIV-1 replication. Phase 1/2.
Features First CDK inhibitor to be used in human clinical trials.
Targets
CDK9 [8]
(Cell-free assay)
CDK1 [8]
(Cell-free assay)
CDK4 [9]
(Cell-free assay)
CDK2 [8]
(Cell-free assay)
CDK6 [9]
(Cell-free assay)
Click to View More Targets
20 nM 30 nM 20-40 nM 40 nM 60 nM
In vitro

Flavopiridol displays less activity against unrelated kinases such as MAP, PAK, PKC, and EGFR with IC50 of >14 μM. Flavopiridol significantly inhibits the colony growth of HCT116, A2780, PC3, and Mia PaCa-2 cells with IC50 of 13 nM, 15 nM, 10 nM and 36 nM, respecitively. [1] Flavopiridol also potently inhibits the activity of Glycogen synthase kinase-3 (GSK-3) with an IC50 of 280 nm. [2] Compared with other CDKs, Flavopiridol inhibits the activity of CDK7 less potently with IC50 of 875 nM. Flavopiridol (0.5 μM) inhibits both pSer807/811 Rb and pThr199 NPM, whereas mild changes are observed at pThr821 Rb. Flavopiridol also decreases the overall RNA polymerase II level, as well as the phosphorylation of RNA polymerase II on the CTD repeats at Ser2 Ser5. [3] As a broad spectrum CDK inhibitor, Flavopiridol can inhibit cell cycle progression in either G1 or G2. Flavopiridol (0.3 μM) induces G1 arrest in either MCF-7 or MDA-MB-468 cells by inhibition of the CDK4 or CDK2 kinase activity. [4] Flavopiridol exhibits potent cytotoxicity against a wide variety of tumor cell lines with IC50 values ranging form 16 nM for LNCAP to 130 nM for K562. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF-7 tumor cell NV\yV2NQWHKxbHnm[ZJifGmxbjDhd5NigQ>? NYTuVJlSUW6qaXLpeIlwdiCxZjDNR2YuPyC2dX3vdkBk\WyuIIDyc4xq\mW{YYTpc44> MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yODh2M{KxNUc,OTB6NEOyNVE9N2F-
PC3 cell NWD2cpg6TnWwY4Tpc44h[XO|YYm= Mn3uTY5pcWKrdHnvckBw\iCSQ{OgZ4VtdCClbH;uc4dmdmmlIHHzd4F6NCCLQ{WwQVExKM7:TR?= M4TtUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzFzME[zOlA6Lz5zMUC2N|YxQTxxYU6=
HCT116 cell M4OzeGZ2dmO2aX;uJIF{e2G7 M4DKTGlvcGmkaYTpc44hd2ZiSFPUNVE3KGOnbHygZ4xwdm:pZX7pZ{Bie3OjeTygTWM2OD1zMzFOwG0> M4\MN|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzFzME[zOlA6Lz5zMUC2N|YxQTxxYU6=
A2780 cell MV7GeY5kfGmxbjDhd5NigQ>? M2f5c2lvcGmkaYTpc44hd2ZiQUK3PFAh[2WubDDjcI9vd2enbnnjJIF{e2G778{MJGlEPTB;MUWg{txO MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOTB4M{[wPUc,OTFyNkO2NFk9N2F-
Mia PaCa-2 cell NGO3boJHfW6ldHnvckBie3OjeR?= MVjJcohq[mm2aX;uJI9nKE2rYTDQZWNiNTJiY3XscEBkdG:wb3flcolkKGG|c3H5MEBKSzVyPUO2JO69VQ>? MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOTB4M{[wPUc,OTFyNkO2NFk9N2F-
LNCaP human prostate carcinoma cell MXPQdo9tcW[ncnH0bY9vKGG|c3H5 MUnJcohq[mm2aX;uJI9nKEyQQ3HQJIh2dWGwIIDyc5N1[XSnIHPhdoNqdm:vYTDj[YxtKHC{b3zp[oVz[XSrb36= MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOjF7MEOxN{c,OTJzOUCzNVM9N2F-
HCT116/VP35 human colon carcinoma cell MUfQdo9tcW[ncnH0bY9vKGG|c3H5 NV7UOGZKUW6qaXLpeIlwdiCxZjDIR3QyOTZxVmCzOUBpfW2jbjDjc4xwdiClYYLjbY5wdWFiY3XscEBxem:uaX\ldoF1cW:wLDDJR|UxRTF5IH7N NWG4U3ZWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUKxPVA{OTNpPkGyNVkxOzF|PD;hQi=>
HCT116 human colon carcinoma cell M1\NSXBzd2yrZnXyZZRqd25iYYPzZZk> MWnJcohq[mm2aX;uJI9nKEiFVEGxOkBpfW2jbjDjc4xwdiClYYLjbY5wdWFiY3XscEBxem:uaX\ldoF1cW:wLDDJR|UxRTF6IH7N MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOjF7MEOxN{c,OTJzOUCzNVM9N2F-
HCT116/VM46 human colon carcinoma cell M1vFNHBzd2yrZnXyZZRqd25iYYPzZZk> MkX0TY5pcWKrdHnvckBw\iCKQ2SxNVYwXk12NjDoeY1idiClb3zvckBk[XKlaX7vcYEh[2WubDDwdo9tcW[ncnH0bY9vNCCLQ{WwQVIyKG6P MlnZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTJzOUCzNVMoRjF{MUmwN|E{RC:jPh?=
A2780/DDP-R human ovarian carcinoma cell M3PER3Bzd2yrZnXyZZRqd25iYYPzZZk> M3y5TmlvcGmkaYTpc44hd2ZiQUK3PFAwTESSLWKgbJVu[W5ib4\hdolidiClYYLjbY5wdWFiY3XscEBxem:uaX\ldoF1cW:wLDDJR|UxRTN6IH7N MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOjF7MEOxN{c,OTJzOUCzNVM9N2F-
ABAE human fibroblast cell NXu3d254WHKxbHnm[ZJifGmxbjDhd5NigQ>? MkHjTY5pcWKrdHnvckBw\iCDQlHFJIh2dWGwIH\pZpJw[myjc4SgZ4VtdCCycn;sbYZmemG2aX;uMEBKSzVyPUS1JI5O NEX2[o09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMkG5NFMyOyd-MUKxPVA{OTN:L3G+
HL60 human leukemia cell NGflUGlRem:uaX\ldoF1cW:wIHHzd4F6 MkfpTY5pcWKrdHnvckBw\iCKTE[wJIh2dWGwIHzleYtmdWmjIHPlcIwheHKxbHnm[ZJifGmxbjygTWM2OD12NjDuUS=> MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOjF7MEOxN{c,OTJzOUCzNVM9N2F-
Hs 27 human fibroblast cell NGrSVIhRem:uaX\ldoF1cW:wIHHzd4F6 M1XuW2lvcGmkaYTpc44hd2ZiSIOgNlchcHWvYX6g[oljem:kbHHzeEBk\WyuIIDyc4xq\mW{YYTpc44tKEmFNUC9OVEhdk1? MknvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTJzOUCzNVMoRjF{MUmwN|E{RC:jPh?=
CCRF-CEM human leukemia cell Ml;lVJJwdGmoZYLheIlwdiCjc4PhfS=> NVjkbo1bUW6qaXLpeIlwdiCxZjDDR3JHNUOHTTDoeY1idiCuZYXr[Y1q[SClZXzsJJBzd2yrZnXyZZRqd25uIFnDOVA:PTJibl2= M3u2SFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF{MUmwN|E{Lz5zMkG5NFMyOzxxYU6=
OVCAR-3 human ovarian carcinoma cell M2DoTnBzd2yrZnXyZZRqd25iYYPzZZk> MXXJcohq[mm2aX;uJI9nKE:YQ1HSMVMhcHWvYX6gc5ZiemmjbjDjZZJkcW6xbXGgZ4VtdCCycn;sbYZmemG2aX;uMEBKSzVyPUW0JI5O NWrjVHdSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUKxPVA{OTNpPkGyNVkxOzF|PD;hQi=>
A2780/DDP-S human ovarian carcinoma cell M4q0dHBzd2yrZnXyZZRqd25iYYPzZZk> M1vM[GlvcGmkaYTpc44hd2ZiQUK3PFAwTESSLWOgbJVu[W5ib4\hdolidiClYYLjbY5wdWFiY3XscEBxem:uaX\ldoF1cW:wLDDJR|UxRTV4IH7N MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOjF7MEOxN{c,OTJzOUCzNVM9N2F-
A2780/TAX-S human ovarian carcinoma cell M3PQWXBzd2yrZnXyZZRqd25iYYPzZZk> NXe4NZFlUW6qaXLpeIlwdiCxZjDBNlc5OC:WQWitV{BpfW2jbjDveoFzcWGwIHPhdoNqdm:vYTDj[YxtKHC{b3zp[oVz[XSrb36sJGlEPTB;NkWgcm0> NEeyPWk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMkG5NFMyOyd-MUKxPVA{OTN:L3G+
LS174T human colon carcinoma cell NGm5b2VRem:uaX\ldoF1cW:wIHHzd4F6 MYLJcohq[mm2aX;uJI9nKEyVMUe0WEBpfW2jbjDjc4xwdiClYYLjbY5wdWFiY3XscEBxem:uaX\ldoF1cW:wLDDJR|UxRTZ3IH7N M{XCS|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF{MUmwN|E{Lz5zMkG5NFMyOzxxYU6=
MCF-7 human breast carcinoma cell NIC0U|BRem:uaX\ldoF1cW:wIHHzd4F6 MULJcohq[mm2aX;uJI9nKE2FRj23JIh2dWGwIHLy[YF{fCClYYLjbY5wdWFiY3XscEBxem:uaX\ldoF1cW:wLDDJR|UxRTZ4IH7N M17sTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF{MUmwN|E{Lz5zMkG5NFMyOzxxYU6=
PC3 human prostate carcinoma cell MWXQdo9tcW[ncnH0bY9vKGG|c3H5 MWDJcohq[mm2aX;uJI9nKFCFMzDoeY1idiCycn;zeIF1\SClYYLjbY5wdWFiY3XscEBxem:uaX\ldoF1cW:wLDDJR|UxRTZ4IH7N M4PPc|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF{MUmwN|E{Lz5zMkG5NFMyOzxxYU6=
MLF mouse lung fibroblast cell MV3Qdo9tcW[ncnH0bY9vKGG|c3H5 M3XwUmlvcGmkaYTpc44hd2ZiTVzGJI1wfXOnIHz1coch\mmkcn;icIF{fCClZXzsJJBzd2yrZnXyZZRqd25uIFnDOVA:PzJibl2= MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOjF7MEOxN{c,OTJzOUCzNVM9N2F-
LX-1 human lung carcinoma MXrQdo9tcW[ncnH0bY9vKGG|c3H5 NVXRPVRsUW6qaXLpeIlwdiCxZjDMXE0yKGi3bXHuJIx2dmdiY3HyZ4lvd22jIIDyc4xq\mW{YYTpc44tKEmFNUC9O|Uhdk1? NGr4d5U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMkG5NFMyOyd-MUKxPVA{OTN:L3G+
A431 human squamous cell NW[3OlVzWHKxbHnm[ZJifGmxbjDhd5NigQ>? NGPVZ3JKdmirYnn0bY9vKG:oIFG0N|EhcHWvYX6gd5F2[W2xdYOgZ4VtdCClYYLjbY5wdWFiY3XscEBxem:uaX\ldoF1cW:wLDDJR|UxRTd3IH7N M4DkR|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF{MUmwN|E{Lz5zMkG5NFMyOzxxYU6=
SKBR-3 human breast carcinoma cell NGWxdWRRem:uaX\ldoF1cW:wIHHzd4F6 M334OWlvcGmkaYTpc44hd2ZiU1vCVk0{KGi3bXHuJIJz\WG|dDDjZZJkcW6xbXGgZ4VtdCCycn;sbYZmemG2aX;uMEBKSzVyPUe3JI5O MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOjF7MEOxN{c,OTJzOUCzNVM9N2F-
A2780/TAX-R human ovarian carcinoma cell NVHmV2ZoWHKxbHnm[ZJifGmxbjDhd5NigQ>? M4DwZmlvcGmkaYTpc44hd2ZiQUK3PFAwXEG[LWKgbJVu[W5ib4\hdolidiClYYLjbY5wdWFiY3XscEBxem:uaX\ldoF1cW:wLDDJR|UxRTd6IH7N M3nndVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF{MUmwN|E{Lz5zMkG5NFMyOzxxYU6=
M109 mouse lung carcinoma cell MXLQdo9tcW[ncnH0bY9vKGG|c3H5 MXfJcohq[mm2aX;uJI9nKE1zMEmgcY92e2VibIXu[{Bk[XKlaX7vcYEh[2WubDDwdo9tcW[ncnH0bY9vNCCLQ{WwQVgxKG6P MmPMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTJzOUCzNVMoRjF{MUmwN|E{RC:jPh?=
CACO-2 human colon carcinoma cell Mn\HVJJwdGmoZYLheIlwdiCjc4PhfS=> MmXBTY5pcWKrdHnvckBw\iCFQVPPMVIhcHWvYX6gZ49td25iY3HyZ4lvd22jIHPlcIwheHKxbHnm[ZJifGmxbjygTWM2OD16NjDuUS=> Ml\zQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTJzOUCzNVMoRjF{MUmwN|E{RC:jPh?=
A549 human lung carcinoma cell M3\6dnBzd2yrZnXyZZRqd25iYYPzZZk> NWTNRVNZUW6qaXLpeIlwdiCxZjDBOVQ6KGi3bXHuJIx2dmdiY3HyZ4lvd22jIHPlcIwheHKxbHnm[ZJifGmxbjygTWM2OD17NjDuUS=> MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOjF7MEOxN{c,OTJzOUCzNVM9N2F-
MIP human colon carcinoma cell MlnUSpVv[3Srb36gZZN{[Xl? NVvqXW91UW6qaXLpeIlwdiCxZjDNTXAhcHWvYX6gZ49td25iY3HyZ4lvd22jIHPlcIwhdGmwZTygTWM2OD1yLkGyJO69VQ>? NGjD[o89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMkG5NFMyOyd-MUKxPVA{OTN:L3G+
K562 human leukemia cell NUfB[VNFWHKxbHnm[ZJifGmxbjDhd5NigQ>? NH2zUWFKdmirYnn0bY9vKG:oIFu1OlIhcHWvYX6gcIV2c2WvaXGgZ4VtdCCycn;sbYZmemG2aX;uMEBKSzVyPUCuNVMh|ryP NVrNToZ4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUKxPVA{OTNpPkGyNVkxOzF|PD;hQi=>
human A2780 cell line NFnUb|FRem:uaX\ldoF1cW:wIHHzd4F6 NXLQ[|BRPzJiaB?= MWPBcpRqeHKxbHnm[ZJifGm4ZTDl[oZm[3RiYXfhbY5{fCCqdX3hckBCOjd6MDDj[YxtKGyrbnWge4F{KGSndHXycYlv\WRiaX6gZUB4cG:uZTDj[YxtKDd{IHjyJIN6fG:2b4jpZ4l1gSCjc4PhfUwhUUN3ME23NUBvVQ>? MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPTB{N{i2N{c,OTVyMke4OlM9N2F-
human ovarian (A2780) cancer cell M{LDc2N6fG:2b4jpZ:Kh[XO|YYm= MY\DfZRwfG:6aXOg[YZn\WO2IH;uJIh2dWGwIH;2ZZJq[W5iKFGyO|gxMSClYX7j[ZIh[2WubDDsbY5mNCCLQ{WwQVcyKG6P NEj5SVc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNUGyOVk4OSd-MUWxNlU6PzF:L3G+
ID8 cells M4\3XXBzd2yrZnXyZZRqd25iYYPzZZk> NHX5UI5CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JGlFQCClZXzsd{whUUN3ME23JI5O MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzF{M{iyNUc,OTdzMkO4NlE9N2F-
MCF7 cells NHnpUIFRem:uaX\ldoF1cW:wIHHzd4F6 MXvBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IF3DSlch[2WubIOsJGlEPTB;Mk[gcm0> NITQUI89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{GyN|gzOSd-MUexNlM5OjF:L3G+
Sf9 cells Mmf6SpVv[3Srb36gZZN{[Xl? NGnEN|NKdmirYnn0bY9vKG:oIILlZ49u[mmwYX70JIN6[2yrbjDBM2NFUzJiZYjwdoV{e2WmIHnuJHNnQSClZXzsd{whUUN3ME2xNkBvVQ>? NI\QOoE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{mwOFM3Pid-MUe5NFQ{PjZ:L3G+
human A2780 cells Mkf5SpVv[3Srb36gZZN{[Xl? NVjLdVVlUW6qaXLpeIlwdiCxZjDj[IsudWWmaXH0[YQhVlCPIIDoc5NxcG:{eXzheIlwdiCjdDD0bJIyQTliaX6gbJVu[W5iQUK3PFAh[2WubIO= NHuzOFE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOES2PVgxQSd-MUi0Olk5ODl:L3G+
human A2780 cells MWTGeY5kfGmxbjDhd5NigQ>? M3jFO|I1KGh? M13pSGlvcGmkaYTpc44hd2ZiY3TrMY1m\GmjdHXkJHJjKHCqb4PwbI9zgWyjdHnvckBifCC2aIK4NlEhcW5iaIXtZY4hSTJ5OECgZ4VtdHNiYX\0[ZIhOjRiaILz MnzvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh2Nkm4NFkoRjF6NE[5PFA6RC:jPh?=
human NCI60 cells Ml\SVJJwdGmoZYLheIlwdiCjc4PhfS=> NHHEZpQ4OiCq MVvBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE6FSU[wJINmdGy|IHHmeIVzKDd{IHjyd{BjgSC|dXzmc5Jpd2SjbXnu[UBDKGG|c3H5MEBIUTVyPUe0Mlchdk1? MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTB6MEewN{c,OjFyOEC3NFM9N2F-
human NCI60 cells M3rJb3Bzd2yrZnXyZZRqd25iYYPzZZk> NELhT404OiCq M4DleGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTlPJOlAh[2WubIOgZZN{\XO|ZXSgZZMhdGW2aHHsJIVn\mWldDDh[pRmeiB5MjDodpMh[nlic4Xs[o9zcG:mYX3pcoUhSiCjc4PhfUwhVEN3ME2wMlkxPCEQvF2= NX\aN2RMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGwPFA4ODNpPkKxNFgxPzB|PD;hQi=>
human A2780 cells MmfvR5l1d3SxeHnjxsBie3OjeR?= MXiyOEBp MmDoR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVI4QDBiY3XscJMh[W[2ZYKgNlQhcHK|IHL5JG1VXCCjc4PhfUwhT0l3ME2yN{BvVQ>? M{HqNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|M{CxO|Y4Lz5{M{OwNVc3PzxxYU6=
human MRC5 cells NGjG[5REgXSxdH;4bYPDqGG|c3H5 M1:5bVczKGh? MlPZR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUXJEPSClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBIUTVyPUK4JI5O NFvJe|M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OwNVc3Pyd-MkOzNFE4Pjd:L3G+
human A2780 cells M1n5T2N6fG:2b4jpZ:Kh[XO|YYm= MVe3NkBp MnnaR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVI4QDBiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JG1VXCCjc4PhfUwhT0l3ME2yPUBvVQ>? MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzNyMUe2O{c,OjN|MEG3Olc9N2F-
human A2780 cells MX3DfZRwfG:6aXRCpIF{e2G7 MUC0PEBp MkDuR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVI4QDBiY3XscJMh[W[2ZYKgOFghcHK|IHL5JG1VXCCjc4PhfUwhT0l3ME2zNUBvVQ>? M{jVRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|M{CxO|Y4Lz5{M{OwNVc3PzxxYU6=
human MRC5 cells MWjDfZRwfG:6aXRCpIF{e2G7 NXz3Z4FHPDhiaB?= MX7DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNVmM2KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO|YYmsJGdKPTB;M{mgcm0> MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzNyMUe2O{c,OjN|MEG3Olc9N2F-
human MRC5 cells MVnDfZRwfG:6aXRCpIF{e2G7 Mm\qNlQhcA>? NHnUdFNEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOWkN3IHPlcIx{KGGodHXyJFI1KGi{czDifUBOXFRiYYPzZZktKEeLNUC9OFkhdk1? MkLTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN|MEG3OlcoRjJ|M{CxO|Y4RC:jPh?=
human HMEC1 cells MVLDfZRwfG:6aXRCpIF{e2G7 MVOyOEBp MWjDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIUWVEOSClZXzsd{Bi\nSncjCyOEBpenNiYomgUXRVKGG|c3H5MEBIUTVyPU[xJI5O MofDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN|MEG3OlcoRjJ|M{CxO|Y4RC:jPh?=
human HMEC1 cells NVPwV5hoS3m2b4TvfIlkyqCjc4PhfS=> NWDnUGxzPDhiaB?= M33yN2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhOTUNzIHPlcIx{KGGodHXyJFQ5KGi{czDifUBOXFRiYYPzZZktKEeLNUC9OlIhdk1? NVnhenZiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzNFE4PjdpPkKzN|AyPzZ5PD;hQi=>
human HMEC1 cells NGHkWo9EgXSxdH;4bYPDqGG|c3H5 M1zBNlczKGh? Mo\nR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTG1GSzFiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JG1VXCCjc4PhfUwhT0l3ME22OkBvVQ>? M{PJN|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|M{CxO|Y4Lz5{M{OwNVc3PzxxYU6=
A2780 NWrmeYR4TnWwY4Tpc44h[XO|YYm= M2fVblM{OCCwTR?= NXnHW2lSOjRiaIK= NV3mcoI4WGW{Y3XueIFo\SCDMke4NEBk\WyuczDpckB{[i2JMTDh[pRmeiB{NDDodkBzKGG2IEOzNEBvVSBqSVO1NEktKEOnbHygZ5lkdGViPTCwMlAxOSEQvF2u MoPuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTJzOUCzNVMoRjF{MUmwN|E{RC:jPh?=
A2780 NH3P[mRCeG:ydH;zbZMh[XO|YYm= M1PkdVM{OCCwTR?= MX[yOEBpeg>? MWjBdI9xfG:2aXOgRVI4QDBiY3XscJMh[W[2ZYKgNlQhcHJicjDheEA{OzBibl2gLGlEPTBrLDDD[YxtKGO7Y3zlJF0hOC5yMEGg{txONg>? M2GwUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF{MUmwN|E{Lz5zMkG5NFMyOzxxYU6=
A2780 M1XvR2Z2dmO2aX;uJIF{e2G7 MW[yPVgxKG6P M{XqTlI1KGi{ MnX3VIVz[2WwdHHn[UBCOjd6MDDj[YxteyCrbjDzeYIuTzFiYX\0[ZIhOjRiaIKgdkBifCB{OUiwJI5OKCiLQ{mwLUwhS2WubDDjfYNt\SB;IECuNFAzKM7:TT6= MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOjF7MEOxN{c,OTJzOUCzNVM9N2F-
A2780 MXzBdI9xfG:|aYOgZZN{[Xl? Mni1Nlk5OCCwTR?= MXiyOEBpeg>? NX;TSppySXCxcITveIlkKEF{N{iwJINmdGy|IHHmeIVzKDJ2IHjyJJIh[XRiMkm4NEBvVSBqSVO5NEktKEOnbHygZ5lkdGViPTCwMlAxQSEQvF2u MmC4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTJzOUCzNVMoRjF{MUmwN|E{RC:jPh?=
A2780 NXziRY1DTnWwY4Tpc44h[XO|YYm= MWiyPVgxKG6P NULIbJhVOjRiaIK= NXLPUllbWGW{Y3XueIFo\SCDMke4NEBk\WyuczDpckBUNXCqYYPlJIFnfGW{IEK0JIhzKHJiYYSgNlk5OCCwTTCoTWM6OCluIFPlcIwh[3mlbHWgQUAxNjBzMjFOwG0v MoL0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTJzOUCzNVMoRjF{MUmwN|E{RC:jPh?=
A2780 MYTGeY5kfGmxbjDhd5NigQ>? M1rvPFM{OCCwTR?= Mlv1NlQhcHJ? MnvsVIVz[2WwdHHn[UBCOjd6MDDj[YxteyCrbjDTMZBp[XOnIHHmeIVzKDJ2IHjyJJIh[XRiM{OwJI5OKCiLQ{WwLUwhS2WubDDjfYNt\SB;IECuNFE3KM7:TT6= MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOjF7MEOxN{c,OTJzOUCzNVM9N2F-
A2780 NGroV5ZHfW6ldHnvckBie3OjeR?= Mn3XN|MxKG6P MkTNNlQhcHJ? MYHQ[ZJk\W62YXflJGEzPzhyIHPlcIx{KGmwIFeyM20h[W[2ZYKgNlQhcHJicjDheEA{OzBibl2gLGlEPTBrLDDD[YxtKGO7Y3zlJF0hOC5yMkOg{txONg>? M4S1cFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF{MUmwN|E{Lz5zMkG5NFMyOzxxYU6=
A2780 MmHnSpVv[3Srb36gZZN{[Xl? NHPpOW4zQThyIH7N MYSyOEBpeg>? M2\uPHBmemOnboTh[4UhSTJ5OECgZ4VtdHNiaX6gS|IwVSCjZoTldkAzPCCqcjDyJIF1KDJ7OECgcm0hMEmFOUCpMEBE\WyuIHP5Z4xmKD1iMD6wNlUh|ryPLh?= MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOjF7MEOxN{c,OTJzOUCzNVM9N2F-
A2780 MY\GeY5kfGmxbjDhd5NigQ>? M2XlRVM{OCCwTR?= NULSc5A5OjRiaIK= NWLyOoxiWGW{Y3XueIFo\SCDMke4NEBk\WyuczDpckBIOSCjZoTldkAzPCCqcjDyJIF1KDN|MDDuUUApUUN3MDmsJGNmdGxiY4njcIUhRSByLkC2JO69VS5? MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOjF7MEOxN{c,OTJzOUCzNVM9N2F-
A2780 MYPGeY5kfGmxbjDhd5NigQ>? NHHYUGMzQThyIH7N NXLnbIpCOjRiaIK= MoiyVIVz[2WwdHHn[UBCOjd6MDDj[YxteyCrbjDHNUBi\nSncjCyOEBpeiC{IHH0JFI6QDBibl2gLGlEQTBrLDDD[YxtKGO7Y3zlJF0hOC5yNkGg{txONg>? NF3tfIQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMkG5NFMyOyd-MUKxPVA{OTN:L3G+
A2780 MnnaSpVv[3Srb36gZZN{[Xl? NX7O[ZBVOjRiaILz NIC3emtKdmirYnn0bY9vKG:oIHPkb{1u\WSrYYTl[EBT[iCyaH;zdIhwenmuYYTpc44h[XRic3XyPFA4NzhzMTDpckBpfW2jbjDBNlc5OCClZXzsd{Bi\nSncjCyOEBpenN? MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDR4OUiwPUc,OTh2Nkm4NFk9N2F-
A2780 MWLGeY5kfGmxbjDhd5NigQ>? MofCNlQhcHK| MUHJcohq[mm2aX;uJI9nKGOma{mtcYVlcWG2ZXSgVm5CKHCxbEKgR3RFKHCqb4PwbI9zgWyjdHnvckBifCC|ZYKyJIlvKGi3bXHuJGEzPzhyIHPlcIx{KGGodHXyJFI1KGi{cx?= MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDR4OUiwPUc,OTh2Nkm4NFk9N2F-
A2780 MW\GeY5kfGmxbjDhd5NigQ>? MVOyOEBpenN? MVfJcohq[mm2aX;uJI9nKGOma{etcYVlcWG2ZXSgVm5CKHCxbEKgR3RFKHCqb4PwbI9zgWyjdHnvckBifCC|ZYK1JIlvKGi3bXHuJGEzPzhyIHPlcIx{KGGodHXyJFI1KGi{cx?= NHPwcVk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOES2PVgxQSd-MUi0Olk5ODl:L3G+
A2780 NYLac21qSXCxcITvd4l{KGG|c3H5 NEHPT4czPCCqcoO= M{Oycmlv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gbJVu[W5iQUK3PFAh[2WubIOgZZN{\XO|ZXSgZZMh[XCyZXHyZY5k\SCxZjDNZ4wyKHC{b4TlbY4hdGW4ZXygZYZ1\XJiMkSgbJJ{ NVrkOWJGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi0Olk5ODlpPkG4OFY6QDB7PD;hQi=>
DR-U2OS-GFP MXXGeY5kfGmxbjDhd5NigQ>? NIjTcG0xNjFidV2= MWK1OkBpenN? NH71bXNT\WS3Y4Tpc44hd2ZiaH;tc4xw\2:3czDy[YNwdWKrbnH0bY9vKGmwIHj1cYFvKESULWWyU3MuT0[SIHPlcIx{KGW6cILld5NqdmdiST3TZ4VKKG63Y3zlZZNmKGG|c3Xzd4VlKGG|IILl[JVkfGmxbjDv[kBTSUR3MTDs[ZZmdCCjdDCwMlEhfU1iYX\0[ZIhPTZiaILzJIJ6KGmvbYXuc4Jtd3S2aX7n MofOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF2MUe0NVcoRjJzNEG3OFE4RC:jPh?=
A2780 MVjGeY5kfGmxbjDhd5NigQ>? M1TxS|I1KGi{cx?= M3fuZmlvcGmkaYTpc44hd2ZiQ1TLPUBqdiCqdX3hckBCOjd6MDDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gc4YhWk6DUFnJJGNVTCCyaH;zdIhwenmuYYTpc44h[XRiU3XyNkBifCCJSUWwJINwdmOnboTyZZRqd25iYX\0[ZIhOjRiaILzJIJ6KFenc4Tldo4h[myxdITpcoch[W6jbInzbZM> M4H0bVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|M{CxO|Y4Lz5{M{OwNVc3PzxxYU6=
A2780 MlfYR4VtdCCleXPs[UBie3OjeR?= MorINlQhcHK| NEfwR29E\WyuIHP5Z4xmKGG{cnXzeEBqdiCqdX3hckBCOjd6MDDj[YxteyCjc4Pld5Nm\CCjczDhZ4N2dXWuYYTpc44h[XRiR{KvUUBxcGG|ZTDheEBt\XO|IIToZY4hT0l3MDDh[pRmeiB{NDDodpMh[nliZnzve{BkgXSxbXX0dolkKGGwYXz5d4l{ NF\ucGE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OwNVc3Pyd-MkOzNFE4Pjd:L3G+
A2780 NW[zW4IzTnWwY4Tpc44h[XO|YYm= NH\YZokzPCCqcoO= NGLWc3NKdmirYnn0bY9vKG:oIFPET|khcW5iaIXtZY4hSTJ5OECgZ4VtdHNiYYPz[ZN{\WRiYYOg[I94dnKnZ4XsZZRqd25ib3[gUWNNOSCjdDDHTVUxKHSxIEXYS2k2OCClb37j[Y51emG2aX;uJIFnfGW{IEK0JIhzeyCkeTDX[ZN1\XKwIHLsc5R1cW6pIHHuZYx6e2m| M1GwOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|M{CxO|Y4Lz5{M{OwNVc3PzxxYU6=
A2780 MYDBdI9xfG:|aYOgZZN{[Xl? NVL0bGpOOjRiaILz NYLKUGxDUW6mdXP0bY9vKG:oIHHwc5B1d3OrczDpckBpfW2jbjDBNlc5OCClZXzsd{Bie3Onc4Pl[EBieyCrbnT1Z5Rqd25ib3[gVGFTWCClbHXheoFo\SCjdDDHTVUxKHSxIEXYS2k2OCClb37j[Y51emG2aX;uJIFnfGW{IEK0JIhzeyCkeTDX[ZN1\XKwIHLsc5R1cW6pIHHuZYx6e2m| M{DRO|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|M{CxO|Y4Lz5{M{OwNVc3PzxxYU6=
A2780 Ml\PSpVv[3Srb36gZZN{[Xl? MlrlNlQhcHK| NYX6[2s{UW6qaXLpeIlwdiCxZjDDSGs6KGmwIHj1cYFvKEF{N{iwJINmdGy|IHHzd4V{e2WmIHHzJIRwf26{ZXf1cIF1cW:wIH;mJGhFVTJiYYSgS2k2OCC2bzC1XGdKPTBiY3;uZ4VvfHKjdHnvckBi\nSncjCyOEBpenNiYomgW4V{fGW{bjDicI91fGmwZzDhcoFtgXOrcx?= NH\MfYE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OwNVc3Pyd-MkOzNFE4Pjd:L3G+
MT4 NU\RVYJxSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= NF;ldGhCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJfW2jbjDpcY12dm:mZX\pZ4lmdmO7II\pdpV{KDFiTlygOE0{KGmwZnXjeIVlKGmwIF3UOEBk\WyuczDt[YF{fXKnZDDvckBl[XliNDDwc5N1KGmwZnXjeIlwdiCkeTDwNlQh[XO|YYmsJGVEPTBiPTCwMlAyPSEQvF2u MkjGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7MUS4NFQoRjJ3OUG0PFA1RC:jPh?=
MT4 Mm\2R5l1d3SxeHnjbZR6KGG|c3H5 MoT3R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUXQ1KGOnbHzzMEBKSzVyIE2gNE4xPjdizszNMi=> MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTlzNEiwOEc,OjV7MUS4NFQ9N2F-
Sf9 M3fkcmZ2dmO2aX;uJIF{e2G7 NIHRSpIyPSCvaX7z NFO3dm5KdmirYnn0bY9vKG:oIFPET|Iw[3mlbHnuJGUyKCi3bnvuc5dvKG:{aXfpckkh\XiycnXzd4VlKGmwIGPmPUBqdnOnY4SgZ4VtdHNidYPpcochXWyrZ3j0R2ZHU06LVmTQVnRRWFCVUVfLMYFucWSnIIP1ZpN1emG2ZTDh[pRmeiBzNTDtbY5{KGK7IHH1eI9z[WSrb3fyZZBpgSxiSVO1NEA:KDBwMUOg{txONg>? NFfnO489[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUmxOFgxPCd-MkW5NVQ5ODR:L3G+
A549 NH3xNmpCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= MYmzJIRigXN? MX\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEF3NEmgZ4VtdHNiYX\0[ZIhOyCmYYnzJIJ6KFOUQjDt[ZRpd2RuIFfJOVAhRSByLkG0JO69VS5? NIX0[ow9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUmxOFgxPCd-MkW5NVQ5ODR:L3G+
DU145 M1PuTmFvfGmycn;sbYZmemG2aY\lJIF{e2G7 M1;NWlMh\GG7cx?= NFTzfG9CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFTVNVQ2KGOnbHzzJIFnfGW{IEOg[IF6eyCkeTDTVmIhdWW2aH;kMEBIUTVyIE2gNE4yPSEQvF2u NFPNc4E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUmxOFgxPCd-MkW5NVQ5ODR:L3G+
KB Mlv6RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? MX[zJIRigXN? M4KyVmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iS1KgZ4VtdHNiYX\0[ZIhOyCmYYnzJIJ6KFOUQjDt[ZRpd2RuIFfJOVAhRSByLkG2JO69VS5? NGLiOVY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUmxOFgxPCd-MkW5NVQ5ODR:L3G+
KBVIN MnL2RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? NFjhe4o{KGSjeYO= NFi0OIhCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFvCWmlPKGOnbHzzJIFnfGW{IEOg[IF6eyCkeTDTVmIhdWW2aH;kMEBIUTVyIE2gNE4yQCEQvF2u MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTlzNEiwOEc,OjV7MUS4NFQ9N2F-
HCT116 MmrQRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? MWi3NkBpenN? NX36UGNmSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIR3QyOTZiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JGNmdGy2aYTldk1IdG9icnXh[4VvfCCkYYPl[EBie3OjeTDpckBxemW|ZX7j[UBw\iBzMDWg[oV1[WxiYn;2bY5mKHOncoXtMEBGSzVyIE2gNE4xOzRizszNMi=> MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjl6NUOwOUc,OjZ7OEWzNFU9N2F-
HCT116 NVrYSpIzSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= MXq3NkBpenN? MYDBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiFVEGxOkBk\WyuczDh[pRmeiB5MjDodpMh[nliQ3XscJRqfGW{LVfsc{Bz\WGpZX70JIJie2WmIHHzd4F6KGmwIIDy[ZNmdmOnIH;mJFAvPjJ3JTDm[ZRidCCkb4\pcoUhe2W{dX2sJGVEPTBiPTCwMlA2QSEQvF2u MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjl6NUOwOUc,OjZ7OEWzNFU9N2F-
Sf9 MnjXSpVv[3Srb36gZZN{[Xl? MkXDNVAhdWmwcx?= NUTp[GUxUW6qaXLpeIlwdiCxZjDoeY1idiCKaYO2MZRi\2enZDDDSGs6N2O7Y3zpckBVOSCneIDy[ZN{\WRiaX6gZoFkfWyxdnnyeZMhcW6oZXP0[YQhe2Z7IHPlcIx{KHW|aX7nJGdUXC2FVFSgZZMhe3Wkc4TyZZRmKGGodHXyJFExKG2rboOgbY4heHKnc3XuZ4Uhd2ZiW3fhcY1iNTN{UG3BWHAh[nliU1TTMXBCT0ViYX7hcJl{cXNuIFnDOVAhRSByLkCwNlUh|ryPLh?= M1Luc|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUexNFM3Lz5{N{G3NVA{PjxxYU6=
Sf21 M3fOXGZ2dmO2aX;uJIF{e2G7 NU[1[oVoUW6qaXLpeIlwdiCxZjDy[YNwdWKrbnHueEBpfW2jbjDmeYxtKGynbnf0bEBENXSncn3pcoFtKEirc{[teIFo\2WmIFPET|kw[3mlbHnuJHQyKGW6cILld5Nm\CCrbjDiZYN2dG:4aYL1d{Bqdm[nY4Tl[EBU\jJzIHnud4VkfCClZXzsd{B2e2mwZzDQSGt1cWSnIHHzJJN2[nO2cnH0[UwhUUN3MDC9JFAvODFzIN88UU4> MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzF5MUCzOkc,OjdzN{GwN|Y9N2F-
HeLa MWnDfZRwfG:6aXPpeJkh[XO|YYm= NVq1dW14PzJiaILz MmTpR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTIVN[SClZXzsd{Bie3Onc4Pl[EBieyCmZXPy[YF{\SCrbjDj[YxtKH[rYXLpcIl1gSCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCFQ{WwJF0hOC5zMjFOwG0v NHPhO3A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{G3NVA{Pid-MkexO|ExOzZ:L3G+
sf21 NInscYtHfW6ldHnvckBie3OjeR?= NETuSGtKdmirYnn0bY9vKG:oIH\1cIwhdGWwZ4ToJIh2dWGwIF6teIVzdWmwYXygTIl{Pi22YXfn[YQhS0SNNj;OMZRmem2rbnHsJGdUXC22YXfn[YQh[3mlbHnuJGQ{KGW6cILld5Nm\CCrbjDz[lIyKGOnbHzzJJV{cW6pIHjpd5RwdmViSEGgd5Vje3S{YYTlMEBKSzVyIE2gNE4{QTVizszNMi=> MkS4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdzN{GwN|YoRjJ5MUexNFM3RC:jPh?=
Sf21 MUfGeY5kfGmxbjDhd5NigQ>? MnLKTY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDoeY1idiCodXzsJIxmdme2aDDDMZRmem2rbnHsJGhqezZvdHHn[4VlKEOGS{evZ5lkdGmwIFivUk11\XKvaX7hcEBIW1RvdHHn[4VlKE2DVEGg[ZhxemW|c3XkJIlvKGKjY4Xsc5ZqenW|IHnu[oVkfGWmIGPmNlEhcW6|ZXP0JINmdGy|IIXzbY5oKGOma{egd5Vje3S{YYTlJJBmeHSrZHWsJGlEPTBiPTCwMlUyPCEQvF2u NXW4fGlCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkexO|ExOzZpPkK3NVcyODN4PD;hQi=>
HepG2 M4LFVmFvfGmycn;sbYZmemG2aY\lJIF{e2G7 NFrpTFM4OiCqcoO= M{nPZmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSHXwS|Ih[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IFPlcHRqfGW{LVfsc{Bie3OjeTygSWM2OCB;IECuNVQ3PCEQvF2u NHH2OY49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSwO|k4PSd-Mkm0NFc6PzV:L3G+
KOPN8 M2q3XWFvfGmycn;sbYZmemG2aY\lJIF{e2G7 MWm3NkBpenN? MmHqRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCNT2DOPEBk\WyuczDh[pRmeiB5MjDodpMh[nliQ3XsWIl1\XJvR3zvJIF{e2G7LDDFR|UxKD1iMD6xPVI3KM7:TT6= NEf1UlM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSwO|k4PSd-Mkm0NFc6PzV:L3G+
SEM NHXZOIdCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= MmS5O|IhcHK| M4m0N2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iU1XNJINmdGy|IHHmeIVzKDd{IHjyd{BjgSCFZXzUbZRmei2JbH:gZZN{[XluIFXDOVAhRSByLkKwOFMh|ryPLh?= M{T4WlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEC3PVc2Lz5{OUSwO|k4PTxxYU6=
UOCB1 NXzkb3p[SW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= NX;1fXg6PzJiaILz NXHRW2xOSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDVU2NDOSClZXzsd{Bi\nSncjC3NkBpenNiYomgR4VtXGm2ZYKtS4xwKGG|c3H5MEBGSzVyIE2gNE4zODh2IN88UU4> MlrHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2MEe5O|UoRjJ7NEC3PVc2RC:jPh?=
KOPN8 M1LFZWFxd3C2b4Ppd{Bie3OjeR?= NGrzd40xNjVidV2= NYTQSXBUOyC2bzCyOEBpenN? MXvJcoR2[3Srb36gc4Yh[XCxcITvd4l{KGmwIHj1cYFvKEuRUF64JINmdGy|IHHzd4V{e2WmIHHzJJVxemWpdXzheIlwdiCxZjDjcIVifmWmIGDBVnAhdGW4ZXygZZQhOC53IIXNJIFnfGW{IEOgeI8hOjRiaILzJIJ6KFenc4Tldo4h[myxdDDhcoFtgXOrcx?= M324dFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEC3PVc2Lz5{OUSwO|k4PTxxYU6=
KOPN8 Ml75RZBweHSxc3nzJIF{e2G7 MX2wMlUhfU1? MmLUNUBpeg>? Mme2TY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCrbjDoeY1idiCNT2DOPEBk\WyuczDhd5Nme3OnZDDhd{B2eHKnZ4XsZZRqd25ib3[gZ4xm[X[nZDDQRXJRKGyndnXsJIF1KDBwNTD1UUBxemVvdILlZZRm\CC5aYToJG5CSyCob4KgNUBpeiCjbnSgcYVie3W{ZXSgZYZ1\XJiMzD0c{AzPCCqcoOgZpkhX2W|dHXyckBjdG:2IHHuZYx6e2m| M4HFOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEC3PVc2Lz5{OUSwO|k4PTxxYU6=
Assay
Methods Test Index PMID
Western blot CDK2 / CDK4 / Cyclin A / p21 / p27 / Rb ; p-ERK / ERK / p-p38 / p-4EBP1 / 4EBP1 / p-S6 ; p-RNAPII / p-eIF4E / Mnk1 ; Cleaved caspase-8 / Cleaved caspase-9 / Cleaved caspase-3 24572052 31193061
Growth inhibition assay Cell viability 31193061
In vivo Administration of Flavopiridol at 7.5 mg/kg for 7 days displays slight antitumor activity against P388 murine leukemia, resulting in %T/C value of 110, and active against the human A2780 ovarian carcinoma implanted sc in nude mice, producing 1.5 log cell kill (LCK). [5] Flavopiridol treatment at 1-2.5 mg/kg for 10 days significantly suppresses collagen-induced arthritis in mice in a dose-dependent manner, by inhibiting synovial hyperplasia and joint destruction, whereas serum concentrations of anti-collagen type II (CII) Abs and proliferative responses to CII are maintained. [6] In the p21-intact Hct116 xenografts in nude mice, administration of CPT-11 (100 mg/kg) followed by Flavopiridol (3 mg/kg) 7 and 16 hours later significantly inhibits tumor regression by 86% and 82%, respectively, displaying >2 fold inhibition compared with CPT-11 alone by 40 %. The combination produces ~30% complete response rate (CR) in contrast to CPT-11 alone where no CR is found. [7]

Protocol (from reference)

Kinase Assay:

[1]

  • CDK kinase assay:

    For CDK1/cyclin B1 kinase assay, kinase reactions consist of 100 ng of baculovirus expressed GST-CDK1/cyclin B1 (human) complex, 1 μg histone HI, 0.2 μCi [γ-33P]ATP, 25 μM ATP in 50 μL kinase buffer (50 mM Tris, pH 8.0, 10 mM MgCl2, 1 mM EGTA, 0.5 mM DTT). For CDK2/cyclin E kinase assay, kinase reactions consist of 5 ng of baculovirus expressed GST-CDK2/cyclin E (human) complex, 0.5 μg GST-RB fusion protein (amino acids 776-928 of retinoblastoma protein), 0.2 μCi [γ-33P]ATP, 25 μM ATP in 50 μL kinase buffer (50 mM Hepes, pH 8.0, 10 mM MgCl2, 1 mM EGTA, 2 mM DTT). For CDK4/cyclin D1 kinase assay, kinase reactions consist of 150 ng of baculovirus expressed GST-CDK4/cyclin D1 (human), 280 ng of Stag-cyclin D1, 0.5 μg GST-RB fusion protein (amino acids 776-928 of retinoblastoma protein), 0.2 μCi [γ-33P]ATP, 25 μM ATP in 50 μL kinase buffer (50 mM Hepes, pH 8.0, 10 mM MgCl2, 1 mM EGTA, 2 mM DTT). Reactions are incubated for 45 minutes for CDK1 and CDK2, or 1 hour for CDK4 at 30 °C and stopped by the addition of cold trichloroacetic acid (TCA) to a final concentration 15%. TCA precipitates are collected onto GF/C unifilter plates using a Filtermate universal harvester and the filters are quantitated using a TopCount 96-well liquid scintillation counter. Flavopiridol is dissolved at 10 mM in dimethylformamide (DMF) and evaluated at six concentrations, each in triplicate. The final concentration of DMF in the assay = 2%. IC50 values are derived by nonlinear regression analysis and have a coefficient of variance = 16%. To assay Flavopiridol activity on CDK6, a filter-binding assay is established. The following are combined in the reaction mixture: 2 μL of CDK6 (0.7 mg/μL), 5 μL of histone H1 (6 mg/mL), 14 μL of kinase buffer (60 mM β-glycerophosphate, 30 mM p-nitrophenyl phosphate, 25 mM MOPS (pH 7.0), 5 mM EGTA, 15 mM MgCl2, 1 mM DTT, 0.1 mM Na-vanadate), 3 μL of increasing concentrations of Flavopiridol diluted in 50% DMSO, and 6 μL of 33P-ATP (1 mCi/mL) in nonradioactive ATP at 90 μM concentration (final concentration: 15 μM). The assay is initiated by the addition of 33P-ATP. The reaction is incubated for 20 minutes at 30°C. A 25 μL aliquot of the supernatant is then spotted onto Whatman P81 phosphocellulose paper. Filters are washed 5 times with 1% phosphoric acid solution. Wet filters are counted in the presence of 1 mL of scintillation fluid. Cdk9 activity is measured using 50 nM of recombinant Cdk9/cyclin T in 50 mM HEPES pH 7.5, 10 mM MgCl2, 1 mM DTT, 3 μM Na3VO4, 150 μM RNA polymerase CDT peptide and 80 μM ATP. Cdk7 assay is performed in the same buffer using 37 nM of purified kinase in the presence of 200 μM ATP and 10 μM myelin binding protein as a substrate. The potency of Flavopiridol toward CDK9 and CDK7 is determined using either a strong anion exchanger (Dowex 1-X8 resin, formate form)-based assay or a scintillation proximity assay. IC50 values are calculated from the dose-response curves.

Cell Research:

[5]

  • Cell lines: MCF-7, LNCAP, PC3, HCT116, CACO-2, A549, HL60, K562 cells and et al.
  • Concentrations: Dissolved in DMSO, final concentrations ~10 μM
  • Incubation Time: 72 hours
  • Method:

    Cells are exposed to various concentrations of Flavopiridol for 72 hours at which time the tetrazolium dye, MTS in combination with phenazine methosulfate, is added. After 3 hours, the absorbency is measured at 492 nm, which is proportional to the number of viable cells. The results are expressed as IC50 values. For cell Cycle analysis, cells are fixed in paraformaldehyde and ethanol, washed, resuspended in staining solution of TdT enzyme and FITC-dUTP, washed, stained with PI following RNase treatment, and then analyzed by flow cytometry.

Animal Research:

[5]

  • Animal Models: Female Balb/c×DBA/2J F1 mice inoculated ip with P388 ascites leukemic cells, and Balb/c nu/nu nude mice subcutaneous implanted with A2780, Br-cycE, or A431 cells
  • Dosages: ~7.5 mg/kg/day
  • Administration: Injection i.p.

Solubility (25°C)

In vitro

In vivo

Add solvents to the product individually and in order
(Data is from Selleck tests instead of citations):
5% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.

2.5mg/mL

Chemical Information

Molecular Weight 401.84
Formula

C21H20ClNO5

CAS No. 146426-40-6
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CN1CCC(C(C1)O)C2=C(C=C(C3=C2OC(=CC3=O)C4=CC=CC=C4Cl)O)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03441555 Completed Drug: Venetoclax|Drug: Alvocidib Acute Myeloid Leukemia (AML) AbbVie|Sumitomo Dainippon Pharma Oncology Inc May 30 2018 Phase 1
NCT03298984 Completed Drug: Alvocidib|Drug: Cytarabine|Drug: Daunorubicin Acute Myeloid Leukemia Sumitomo Dainippon Pharma Oncology Inc September 25 2017 Phase 1

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Flavopiridol (L86-8275) | Flavopiridol (L86-8275) supplier | purchase Flavopiridol (L86-8275) | Flavopiridol (L86-8275) cost | Flavopiridol (L86-8275) manufacturer | order Flavopiridol (L86-8275) | Flavopiridol (L86-8275) distributor